curriculum vitæ - Campus Neurológico Sénior

CURRICULUM VITÆ
Joaquim José Coutinho Ferreira
Lisboa
2013
Identificação
Joaquim Ferreira, nascido a 30 de Novembro de 1968, natural de Torres Vedras.
Educação
Curso Complementar (11º ano) na Escola Secundária n.º 1 de Torres Vedras, com a
média final de 19 valores.
12º ano na Escola Secundária n.º 2 de Torres Vedras, com a média final de 20
valores.
Admissão no Curso de Medicina da Faculdade de Medicina de Lisboa (FML), com a
média de candidatura de 19,8 valores.
Licenciatura em Medicina pela FML (1992), com a média final de 17 valores (Bom
com Distinção).
Especialista em Neurologia pelo Hospital de Santa Maria (HSM) [2001], com a
classificação final de 19,7 valores.
Especialista em Farmacologia Clínica pela Ordem dos Médicos (2008).
Doutoramento em Medicina (Neurologia) pela FML, Universidade de Lisboa, 2009.
Actividade Assistencial
Membro do Grupo de Doenças do Movimento, Serviço de Neurologia, HSM, 1991 – .
Interno do Internato Geral, HSM, Janeiro 1993 – Dezembro 1994.
Interno do Internato Complementar de Neurologia, Serviço de Neurologia, HSM,
Janeiro 1995 – Fevereiro 2001.
Coordenador tratamentos com toxina botulínica, Serviço de Neurologia, HSM, 1998 –
Dezembro 2011.
Assistente Eventual de Neurologia, Serviço de Neurologia, HSM, Março 2001 –
Outubro 2001.
Assistente Eventual de Neurologia, Serviço de Neurologia, Hospital de São José,
Outubro 2001 – Dezembro 2002.
Assistente Hospitalar de Neurologia, Serviço de Neurologia, Hospital Rainha Santa
Isabel (Torres Novas), Dezembro 2002 – Julho 2003.
Assistente Hospitalar de Neurologia, Serviço de Neurologia, Hospital de Santa Maria
(Lisboa), Julho 2003 – .
Cargos e Funções Académicas
Monitor de Anatomia II, FML, 1988 – 1990.
Assistente Livre de Terapêutica Geral, FML, 1995-1998; Assistente convidado, Junho
1998 – 2009.
Responsável pela cadeira de Neurofisiologia do Curso Superior de Terapêutica
Ocupacional (Escola Superior de Saúde de Alcoitão), ano lectivo de 1996/97.
Responsável pela cadeira de Neurologia do Curso Superior de Terapêutica da Fala
(Escola Superior de Saúde de Alcoitão), 1997 – 2001.
Docente convidado da cadeira de Formação Complementar (6º ano), FML, 2000 –
2001.
Assistente de Neurologia da FML com dupla titulação (afecto à Cadeira de
Terapêutica Geral) 2001 – 2009.
Docente convidado dos Mestrados de Neurociências, Medicina do Sono, Educação
Médica e Cuidados Paliativos da FML.
Docente convidado da Cadeira de Neurologia da Licenciatura em Nutrição, FML, ano
lectivo de 2008/09.
Docente convidado do módulo de Doenças Neurodegenerativas do Programa
Doutoral para Médicos da Gulbenkian, 2009 – .
Responsável pelo módulo Therapeutic Research in Neurosciences do Programa de
Mestrado/Doutoramento em Neurociências da FML, 2009 – .
Professor Auxiliar Convidado de Terapêutica Geral e Neurologia da FML a 30%, 2009
- 2012.
Professor Associado Convidado de Terapêutica Geral e Neurologia da FML a 100%,
2012 – .
Actividades no domínio da farmacologia clínica
Coordenador do Movement Disorders Cochrane Review Group, Junho 1996 – 2011.
Membro do Centro de Medicina Baseada na Evidência, FML, Dezembro 1997 – 2002.
Consultor do Centro de Farmacovigilância Sul, FML, Outubro de 2000 – .
Secretário do painel de Neurofarmacologia da European Federation of Neurological
Societies (EFNS), 2000 – 2003.
Actividades de investigação
Membro do Centro de Neurociências de Lisboa, 1992 – 2002.
Estagiário no Laboratório de Farmacologia Médica e Clínica e Centro de Investigação
Clínica, Toulouse, França, 1999 – 2000.
Investigador do Instituto de Medicina Molecular (IMM), 2002 – 2009.
Investigador Principal do Instituto de Medicina Molecular (IMM), 2009 – .
Cargos em Sociedades Científicas Nacionais
Assessor da Comissão de Jovens da Sociedade Portuguesa de Neurologia (SPN),
2000 – 2005.
Secretário da Secção de Doenças do Movimento da SPN, Novembro 2001 – 2005.
Membro da Comissão de Ensino da SPN, 2005 – 2007.
Vice-presidente da Secção de Doenças do Movimento da SPN, Novembro 2006 –
2008.
Responsável pelo Grupo de Trabalho da SPN sobre Creditação, 2008 – 2010.
Cargos em Sociedades Científicas Internacionais
Membro do Steering Committee of Trainees and Junior Neurologists da European
Federation of Neurological Societies, Setembro 1998 – Setembro 2001.
Vice-presidente da European Association for Young Neurologists and Neurology
Trainees (YNT), Setembro 1999 – 2001.
Membro do Comité de Educação da Movement Disoders Society (MDS), 2003 – .
Membro do Comité de Relações Públicas e Ligação da MDS, 2004 – 2006.
Membro do Scientific and Bioethics Advisory Committee da Rede European
Huntington Disease Network (Euro-HD), 2006 – 2010.
Membro do Grupo de Trabalho da “Website” da MDS, 2007 – 2008.
Membro do Comité Executivo da Secção Europeia da MDS, 2007 – 2011.
Membro do Comité Executivo da Rede Euro-HD, Setembro 2008 – .
Membro do Web Site Editorial Board da MDS, 2008 – 2011.
Actividades de coordenação
Coordenador do Cochrane Movement Disorders Review Group da Cochrane
Collaboration, Junho de 1996 – 2011.
Coordenador da Unidade de Ensaios Clínicos da Unidade de Neurofarmacologia do
Centro de Neurociências de Lisboa e posteriormente da Unidade Neurológica de
Investigação Clínica do IMM, 2000 – .
Responsável pelo Comité de Educação da Secção Europeia da MDS, Agosto 2008 – .
Coordenador do Grupo de Trabalho sobre Tratamentos Neuroprotectores da EuroHD, 2008 – .
Responsável pelo Comité de Relações Públicas e Ligação da MDS, 2009 – 2011.
Director Científico da Rede European Huntington Disease Network, 2010 – .
Co-responsável pelo Comité de Membros, Relações Públicas e Ligação da MDS, 2011
–.
Director do Laboratório de Farmacologia Clínica e Terapêutica da FML, 2011 – .
Regente das Disciplinas de Farmacologia Clínica da FML, 2011 – .
Presidente da Sociedade Portuguesa de Doenças do Movimento, 2012 – .
Orientação de formação e projectos académicos
Orientador de formação de 3 internos de neurologia (2 concluídos).
Orientador de 9 teses do Mestrado Integrado em Medicina da FML.
Orientador de 3 projectos de mestrado em neurociências e 6 projectos de
dissertação de doutoramento, em curso.
Outras actividades
Editor das publicaçoes: Journal of Parkinson’s Disease, Journal of Huntington’s
Disease and Frontiers in Movement Disoders.
Revisor das publicações: CNS Drugs, European Journal of Neurology, Movement
Disorders Journal, Expert Review of Neurotherapeutics, Expert Opinion on Drug
Safety, Aging Health, The Journal of Pain, Journal of Neurology, Neuroscience
Letters, Sinapse, Journal of Neurology Neurosurgery and Psychiatry, Journal of
Medical Ethics, Journal of Neural Transmission, The European Neurological Journal,
Dovepress, Expert Opinion On Drug Metabolism and Toxicology, Parkinsonism and
Related Disorders.
Principais Áreas de Interesse
Doenças do Movimento, Doença de Parkinson, Distonias, Doença de Huntington,
Neurofarmacologia Clínica, Ensaios Clínicos.
Comunicações em reuniões científicas
238 comunicações em reuniões científicas nacionais e internacionais
Trabalhos publicados
121 artigos publicados ou aceites para publicação
12 capítulos de livros
Publicações
1. FERREIRA JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G,
Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P,
Poewe W, Rascol O, Sampaio C, Schüpbach M, Tolosa E, Trenkwalder C, Schapira
A, Berardelli A, Oertel WH. Summary of the recommendations of the EFNS/MDS-ES
review on therapeutic management of Parkinson's disease. Eur J Neurol. 2013
Jan;20(1):5-15.
2. Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks D, Burn
DJ, Colosimo C, Fanciulli A, FERREIRA JJ, Gasser T, Grandas F, Kanovsky P,
Kostic V, Kulisevsky J, Oertel W, Poewe W, Reese JP, Relja M, Ruzicka E, Schrag A,
Seppi K, Taba P, Vidailhet M. EFNS/MDS-ES recommendations for the diagnosis of
Parkinson's disease. Eur J Neurol. 2013 Jan;20(1):16-34.
3. Caldeira D, Fernandes RM, Costa J, David C, Sampaio C, FERREIRA JJ. Branded
vs. generic clopidogrel in cardiovascular diseases: a systematic review. J
Cardiovasc Pharmacol. 2012 Nov 26. [Epub ahead of print]
4. FERREIRA JJ, Neutel D, Mestre TA, Galitzky M, Thalamas C, Santos AT, Sampaio
C, Rascol O. Usefulness of OSLER test in Parkinson's disease. Sleep Med. 2013
Mar;14(3):297-8.
5. Chinnapongse RB, Lew MF, FERREIRA JJ, Gullo KL, Nemeth PR, Zhang
FERREIRA JJ.Immunogenicity and long-term efficacy of botulinum toxin type B in
the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Clin
Neuropharmacol. 2012 Sep;35(5):215-23.
6. Coelho M, FERREIRA JJ. Late-stage Parkinson disease. Nat Rev Neurol. 2012
Aug;8(8):435-42.
7. Mestre TA, FERREIRA JJ. An evidence-based approach in the treatment of
Huntington's disease. Parkinsonism Relat Disord. 2012;18(4):316-20.
8. Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P,
Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, GomezTortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali
M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente
D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS;
PREDICT-HD study of the Huntington Study Group (HSG), Landwehrmeyer GB;
REGISTRY study of the European Huntington's Disease Network, Myers RH; HDMAPS Study Group, MacDonald ME, Gusella JF; COHORT study of the HSG. CAG
repeat expansion in Huntington disease determines age at onset in a fully
dominant fashion. Neurology. 2012 Mar 6;78(10):690-5.
9. Mestre TA, Lang AE, FERREIRA JJ, Almeida V, de Carvalho M, Miyasaki J, Chen
R,Fox S. Associated movement disorders in orthostatic tremor. J Neurol Neurosurg
Psychiatry. 2012;83(7):725-9.
10. Rodrigues SM, de Carvalho M, Mestre T, FERREIRA JJ, Coelho M, Peralta R, Vale
P. Paralytic shellfish poisoning due to ingestion of Gymnodinium catenatum
contaminated cockles - Application of the AOAC HPLC Official Method. Toxicon.
2012;59(5):558-66.
11. Quarrell OW, Handley O, O'Donovan K, Dumoulin C, Ramos-Arroyo M, Biunno I,
Bauer P, Kline M, Landwehrmeyer GB, European Huntington’s Disease Network.
Discrepancies in reporting the CAG repeat lengths for Huntington's disease. Eur J
Hum Genet. 2012;20(1):20-6.
12. Valadas A, Coelho M, Mestre T, Guedes LC, Finisterra M, Noronha A, Rosa MM,
Sampaio C, FERREIRA JJ. What motivates Parkinson's disease patients to enter
clinical trials? Parkinsonism and Related Disorders. 2011;17(9):667-71.
13. Teodoro T, Pires D, Rosa MM, Coelho M, Sampaio C, FERREIRA JJ. Has
"levodopa-induced neuropathy" been reported in Parkinson's disease clinical trials?
Mov Disord. 2011;26(10):1966–1967.
14. Orth M, European Huntington's Disease Network, Handley OJ, Schwenke C,
Dunnett S, Wild EJ, Tabrizi SJ, Landwehrmeyer GB. Observing Huntington's
disease: the European Huntington's Disease Network's REGISTRY. J Neurol
Neurosurg Psychiatry. 2011;82(12):1409-12.
15. López-Sendón JL, Royuela A, Trigo P, Orth M, Lange FERREIRA JJ, Reilmann R,
Keylock J, Rickards FERREIRA JJ, Piacentini S, Squitieri F, Landwehrmeyer B,
Witjes-Ane MN, Jurgens, CK, Roos RA, Abraira V, de Yébenes JG; and the
European HD Network. What is the impact of education on Huntington's disease?
Mov Disord. 2011;26(8):1489-95.
16. Martins M, Rosa A, Guedes LC, Benedita V, Gotovac K, Violante S, Mestre T, Coelho
M, Rosa MM, Martin ER, Vance J, Outeiro T, Wang L, Borovecki F, FERREIRA JJ,
Oliveira S, Convergence of miRNA Expression Profiling, α-Synuclein Interacton and
GWAS in Parkinson's Disease. PLoS One. 2011;6(10).
17. Reimão S, Morgado C, Neto L, FERREIRA JJ, Coelho M, Rosa MM, Campos J.
Diffusion Tensor Imaging in Movement Disorders: Review of Major Patterns and
Correlation with Normal Brainstem/cerebellar White Matter. The Neuroradiology
Journal 24: 177-186, 2011.
18. Rickards FERREIRA JJ, Souza JD, Crooks J, van Walsem MR, van Duijn E,
Landwehrmeyer B, Squitieri F, Simpson SA. Discriminant Analysis of Beck
Depression Inventory and Hamilton Rating Scale for Depression in Huntington's
Disease. J Neuropsychiatry Clin Neurosci. 2011. 1;23(4):399-402.
19. Saft C, Epplen JT, Wieczorek S, Landwehrmeyer GB, Roos RA, de Yebenes JG,
Dose M, Tabrizi SJ, Craufurd D. REGISTRY Investigators of the European
Huntington's Disease Network, Arning L. NMDA receptor gene variations as
modifiers in Huntington disease: a replication study. PLoS Curr. 2011 Oct 4;3.
20. Orth M, Carsten S. Age-at-onset in Huntington disease. PLoS Curr. Edited: Dec 21,
2011
21. Goetz CG, Stebbins GT, Theeuwes A, Stocchi F, FERREIRA JJ, van de Witte S,
Bronzova J.Temporal stability of the Unified Dyskinesia Rating Scale. Mov Disord.
2011;(14):2556-9.
22. Mestre TA, FERREIRA JJ. An evidence-based approach in the treatment of
Huntington's disease. Mestre TA, FERREIRA JJ. Parkinsonism Relat Disord. 2011
Dec 15.
23. Rascol O, FERREIRA JJ, Nègre-Pages L, Perez-Lloret S, Lacomblez L, Galitzky M,
Lemarié JC, Corvol JC, Brotchie JM, Bossi L. A proof-of-concept, randomized,
placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's
disease. Fundam Clin Pharmacol. 2011 May 18. [Epub ahead of print]
24. Orth M; European Huntington's Disease Network, Handley OJ, Schwenke C,
Dunnett SB, Craufurd D, Ho A, Wild EJ, Tabrizi SJ. Observing Huntington's Disease:
the European Huntington's Disease Network's REGISTRY. PLoS Curr. 2010;28(2).
25. Rosa MM, FERREIRA JJ, Coelho M, Freire R, Sampaio C. Prescribing Patterns of
Antiparkinsonian Agents in Europe. Mov Disord. 2010;25(8):1053-1060.
26. Coelho M, Marti MJ, Tolosa E, FERREIRA JJ, Valldeoriola F, Rosa M, Sampaio C.
Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. J Neurol.
2010;257(9):1524-1532.
27. Sampaio C, FERREIRA JJ, Parkinson’s Disease: adjunctive entacapone therapy
increases risk of dyskinesia. Nat Rev Neurol. 2010;6(11):590-591.
28. Sampaio C, FERREIRA JJ. A double-blind delayed-start trial of rasagiline in
Parkinson's disease. Nat Rev Neurol. 2010;6(3):126-128.
29. Högl B, Arnulf I, Comella C, FERREIRA JJ, Iranzo A, Tilley B, Trenkwalder C,
Poewe W, Rascol O, Sampaio C, Stebbins GT, Schrag A and Goetz CG. Scales to
Assess Sleep Impairment in Parkinson's Disease: Critique and Recommendations.
Mov Disord. 2010;25(16):2704-16.
30. Louis E, FERREIRA JJ. How Comon is the Most Common Adult Movement
Disorder? Update on the Worldwide Prevalence of Essential Tremor. Mov Disord.
2010;25(5):534-541.
31. FERREIRA JJ, Neutel D, Mestre T, Coelho M, Rosa MM, Rascol O, Sampaio C.
Skin cancer and Parkinson’s disease. Mov Disord. 2010;25(2):139-148.
32. Mestre T, FERREIRA JJ. Pharmacotherapy in Parkinson’s disease: case studies.
Ther Adv Neurol Disord. 2010;3(2):117-26.
33. Correia Guedes L, FERREIRA JJ, Rosa MM, Coelho M, Bonifati V, Sampaio C.
Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: A
systematic review. Parkinsonism Relat Disord. 2010;16(4): 237-242.
34. FERREIRA JJ, Rascol O, Poewe W, Sampaio C, Rocha JF, Nunes T, Almeida L,
Soares da Silva P. A Double-Blind, Randomized, Placebo and Active-Controlled
Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's
Disease. CNS Neuroscience & Therapeutics. 2010;16(6):337-347.
35. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston
FERREIRA JJ, Melamed E, Poewe FERREIRA JJ, Stocchi F, Tolosa E; ADAGIO
Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's
disease. N Engl J Med. 2009;361(13):1268-78.
36. Di Fonzo A, Fabrizio E, Thomas A, Fincati E, Marconi R, Tinazzi M, Breedveld GJ,
Simons EJ, Chien HF, FERREIRA JJ, Horstink MW, Abbruzzese G, Borroni B,
Cossu G, Dalla Libera A, Fabbrini G, Guidi M, De Mari M, Lopiano L, Martignoni E,
Marini P, Onofrj M, Padovani A, Stocchi F, Toni V, Sampaio C, Barbosa ER, Meco G;
Italian Parkinson Genetics Network, Oostra BA, Bonifati V. GIGYF2 mutations are
not a frequent cause of familial Parkinson's disease. Parkinsonism Relat Disord.
2009 (9):703-5.
37. Foreid H, Coelho M, FERREIRA JJ, Ferro J. Reversible iatrogenic subacute
cerebellar syndrome, myoclonus and MRI findings following metronidazole
administration. BMJ Case Reports 2009 [doi:10.1136/bcr.05.2009.1841]
38. Aziz NA, Jurgens CK, Landwehrmeyer GB, van Roon-Mom WM, van Ommen GJ,
Stijnen T, Roos RA, Orth M, Handley OJ, Schwenke C, Ho A, Wild EJ, Tabrizi SJ,
Landwehrmeyer GB; EHDN Registry Study Group. Normal and mutant HTT interact
to affect clinical severity and progression in Huntington disease. Neurology.
2009;73(16):1280-5.
39. Gouveia LO, Castanho P, FERREIRA JJ. Safety of chiropractic interventions: a
systematic review. Spine. 2009;34(11):E405-13
40. Mestre T, FERREIRA JJ, Coelho M, Rosa M, Sampaio C. Therapeutic interventions
for disease progression in Huntington's disease. Cochrane Database Syst Rev.
2009;(3):CD006455.
41. Mestre T, FERREIRA JJ, Coelho M, Rosa M, Sampaio C. Therapeutic interventions
for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev.
2009;(3):CD006456.
42. Mestre T, FERREIRA JJ, Jain S. A multimodal approach to physical therapy in
Parkinson's disease: Optimizing strategies. Mov Disord. 2009;24(6):946.
43. Mestre T, FERREIRA JJ. Eslicarbazepine acetate: a new option for the treatment
of focal epilepsy. Expert Opin Investig Drugs. 2009;18(2):221-9.
44. Ross OA, Spanaki C, Griffith A, Lin CH, Kachergus J, Haugarvoll K, Latsoudis
FERREIRA JJ, Plaitakis A, FERREIRA JJ, Sampaio C, Bonifati V, Wu RM,
Zabetian CP, Farrer MJ. Haplotype analysis of Lrrk2 R1441H carriers with
parkinsonism. Parkinsonism Relat Disord. 2009;15(6):466-7.
45. Stowe RL, Ives NJ, Clarke C, van Hilten J, FERREIRA JJ, Hawker RJ, Shah L,
Wheatley K, Gray R. Dopamine agonist therapy in early Parkinson's disease.
Cochrane Database Syst Rev. 2008;16;(2).
46. FERREIRA JJ, Finisterra M, Noronha A, Mestre T. Centro de Investigação Clínica
como Unidade Funcional da Investigação Biomédica, Sinapse 2008;8(2):27-31.
47. Silveira-Moriyama L, Guedes LC, Kingsbury A, Ayling FERREIRA JJ, Shaw K,
Barbosa ER, Bonifati V, Quinn NP, Abou-Sleiman P, Wood NW, Petrie A, Sampaio
C, FERREIRA JJ, Holton J, Revesz T, Lees AJ. Hyposmia in G2019S LRRK2-related
parkinsonism: Clinical and pathologic data. Neurology 2008;71;1021-1026.
48. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J,
Zabetian CP, Goldwurm S, FERREIRA JJ, Tolosa E, Kay DM, Klein C, Williams DR,
Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP,
Gasser T, Lees AJ, Wood NW; International LRRK2 Consortium. Phenotype,
genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's
disease: a case-control study. Lancet Neurol. 2008;7(7):583-90.
49. FERREIRA JJ, Almeida L, Cunha L, Ticmeanu M, Rosa MM, Januário C, Mitu CE,
Coelho M, Correia-Guedes L, Morgadinho A, Nunes T, Wright LC, Falcão A,
Sampaio C, Soares-da-Silva P. Effects of nebicapone on levodopa
pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in
patients with Parkinson disease. Clin Neuropharmacol. 2008;31(1):2-18.
50. Fernandes R, FERREIRA JJ, Sampaio C. The placebo response in studies of acute
migraine.J Pediatr. 2008;152(4):527-33.
51. Pappert EJ, Germanson T for The Myobloc/Neurobloc European Cervical Dystonia
Study Group, Botulinum Toxin Type B vs. Type A in Toxin-Naive Patients with
Cervical Dystonia: Randomized, Double-Blind, Noninferiority Trial. Mov Disord.
2008;23(4):510-517.
52. Costa J, Rocha ML, Ferreira JJ, Evangelista T, Coelho M, de Carvalho M. Botulinum
toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic
lateral sclerosis. J Neurol. 2008;255 (4):545-50.
53. Coelho M, FERREIRA JJ, Rosa M, Sampaio C. Treatment options for non-motor
symptoms in late-stage Parkinson's disease. Expert Opin Pharmacother. 2008
Mar;9(4):523-35.
54. Gouveia LO, Castanho P, FERREIRA JJ, Guedes MM, Falcão F, e Melo TP.
Chiropractic manipulation: reasons for concern? Clin Neurol Neurosurg. 2007
Dec;109(10):922-5.
55. Atadzhanov M, Mwaba P, de Carvalho M, Costa J, FERREIRA JJ. Upper limb
tremor induced by peripheral nerve injury. Neurology 2007;69:1381.
56. Fonseca AC, FERREIRA JJ, Albuquerque L, Ferro JM. Sneeze as a precipitating
factor of cerebral venous thrombosis. Eur J Neurol 2007;14:7-8.
57. FERREIRA JJ, Silva JM, Freire R, Pignatelli J, Guedes LC, Feijo A et al. Skin
cancers and precancerous lesions in Parkinson's disease patients. Mov Disord
2007;22:1471-5.
58. Di Fonzo A, Chien HF, Socal M, Giraudo S, Tassorelli C, Iliceto G et al. ATP13A2
missense mutations in juvenile parkinsonism and young onset Parkinson disease.
Neurology 2007;68:1557-62.
59. FERREIRA JJ, Guedes LC, Rosa MM, Coelho M, van Doeselaar M, Schweiger D et
al. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease
in Portugal. Mov Disord 2007;22:1194-201.
60. Mestre TA, FERREIRA JJ, Pimentel J. Putaminal petechial haemorrhage as the
cause of non-ketotic hyperglycaemic chorea: a neuropathological case correlated
with MRI findings. J Neurol Neurosurg Psychiatry 2007;78:549-50.
61. FERREIRA JJ, Costa J, Coelho M, Sampaio C. The management of cervical
dystonia. Expert Opin Pharmacother 2007;8:129-40.
62. Goetz CG, Damier P, Hicking C, Laska E, Muller T, Olanow CW et al. Sarizotan as a
treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled
trial. Mov Disord 2007;22:179-86.
63. Poewe W, FERREIRA JJ, Wolters E, Emre M, Onofrj M, Hsu C, Tekin S, Lane R,
on behalf of the EXPRESS Investigators. Long-Term Benefits of Rivastigmine in
Dementia Associated With Parkinson’s Disease: An Active Treatment Extension
Study. Mov Disord 2006;21 (4):456–461.
64. Kappos L, Antel J, Comi G, Montalban X, O’Connor P, Polman CH et al for the
FTY720 D2201 Study Group. Oral Fingolimod (FTY720) for Relapsing Multiple
Sclerosis. N Engl J Med 2006;355:1124-40.
65. Castro-Caldas A, Delwaide P, Jost FERREIRA JJ, Merello M, Williams A, Lamberti
P et al. The Parkinson-Control study: a 1-year randomized, double-blind trial
comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early
combination with levodopa in Parkinson's disease. Mov Disord 2006;21:500-9.
66. Olanow CW, Schapira AH, LeWitt PA, Kieburtz K, Sauer D, Olivieri G et al. TCH346
as a neuroprotective drug in Parkinson's disease: a double-blind, randomised,
controlled trial. Lancet Neurol 2006;5:1013-20.
67. Correa Neto FERREIRA JJ, Cardoso F, Teixeira AL Jr, Maia DP, Beato R, Ferreira
J. The chorea of Zeze. Acta Med Port 2006;19:127-32.
68. Costa J, Henriques R, Barroso C, Ferreira J, Atalaia A, de Carvalho M. Upper limb
tremor induced by peripheral nerve injury. Neurology 2006;67:1884-6.
69. FERREIRA JJ, Couto M, Costa J, Coelho M, Rosa MM, Sampaio C. Botulinum toxin
for the treatment of pain syndromes. Acta Reumatol Port 2006;31:49-62.
70. Montastruc JL, Sommet A, Olivier P, Bagheri FERREIRA JJ, Gony M, LapeyreMestre M et al. Drugs, Parkinson's disease and parkinsonian syndroms: recent
advances in pharmacovigilance. Therapie 2006;61:29-38.
71. FERREIRA JJ, Desboeuf K, Galitzky M, Thalamas C, Brefel-Courbon C, Fabre N et
al. Sleep disruption, daytime somnolence and 'sleep attacks' in Parkinson's disease:
a clinical survey in PD patients and age-matched healthy volunteers. Eur J Neurol
2006;13:209-14.
72. Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Rohe CF et al.
Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's
disease. Eur J Hum Genet 2006;14:322-31.
73. Rascol O, Brooks DJ, Melamed E, Oertel WH, Poewe W, FERREIRA JJ, Stocchi F
et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and
motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given
Once daily, study): a randomised, double-blind, parallel-group trial. Lancet
2005;365:947-54.
74. Goldwurm S, Di Fonzo A, Simons EJ, Rohe CF, Zini M, Canesi M et al. The G6055A
(G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's
disease and originates from a common ancestor. J Med Genet 2005;42(11):e65.
75. Ferreira J, Sampaio C. Essential tremor. Clin Evid 2005;1608-21.
76. Geser F, Seppi K, Stampfer-Kountchev M, Kollensperger M, Diem A, Ndayisaba JP
et al. The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural
Transm 2005;112:1677-86.
77. Di Fonzo A, Rohe CF, Ferreira J, Chien HF, Vacca L, Stocchi F et al. A frequent
LRRK2 gene mutation associated with autosomal dominant Parkinson's disease.
Lancet 2005;365:412-5.
78. Costa J, Espirito-Santo C, Borges A, FERREIRA JJ, Coelho M, Moore P et al.
Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev
2005;CD004900.
79. Costa J, Espirito-Santo C, Borges A, FERREIRA JJ, Coelho M, Moore P et al.
Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database Syst Rev
2005;CD004899.
80. Costa J, Espirito-Santo C, Borges A, FERREIRA JJ, Coelho M, Moore P et al.
Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev
2005;CD004315.
81. Costa J, Borges A, Espirito-Santo C, Ferreira J, Coelho M, Moore P et al. Botulinum
toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane
Database Syst Rev 2005;CD004314.
82. Costa J, Espirito-Santo C, Borges A, FERREIRA JJ, Coelho M, Sampaio C.
Botulinum toxin type A versus anticholinergics for cervical dystonia. Cochrane
Database Syst Rev 2005;CD004312.
83. Costa J, Espirito-Santo C, Borges A, FERREIRA JJ, Coelho M, Moore P et al.
Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev
2005;CD003633.
84. Salinas RA, Alvarez G, Ferreira J. Corticosteroids for Bell's palsy (idiopathic facial
paralysis). Cochrane Database Syst Rev 2004;CD001942.
85. Coelho M, FERREIRA JJ, Dias B, Sampaio C, Pavao Martins I, Castro-Caldas A.
Assessment of time perception: the effect of aging. J Int Neuropsychol Soc
2004;10:332-41.
86. Sampaio C, Costa J, FERREIRA JJ. Clinical comparability of marketed formulations
of botulinum toxin. Mov Disord 2004;19 Suppl 8:S129-36.
87. Ziegler M, Castro-Caldas A, Del Signore S, Rascol O. Efficacy of piribedil as early
combination to levodopa in patients with stable Parkinson's disease: a 6-month,
randomized, placebo-controlled study. Mov Disord 2003;18:418-25.
88. Rascol O, Brefel-Courbon C, Payoux P, Ferreira J. The management of patients
with early Parkinson's disease. Adv Neurol 2003;91:203-11.
89. Salinas RA, Alvarez G, Alvarez MI, Ferreira J. Corticosteroids for Bell's palsy
(idiopathic facial paralysis). Cochrane Database Syst Rev 2002;CD001942.
90. Rascol O, Brefel-Courbon C, Payoux P, FERREIRA JJ. Medical treatment of LDopa induced dyskinesias. In FERREIRA JJ Mizuno et al (ed) “Advances in
Behavioral Biology”, Vol 51, 409-415, Kluwer Academic/Plenum Publishers, 2002.
91. Rascol O, Payoux P, FERREIRA JJ, Brefel-Courbon C. The management of
patients with early Parkinson's disease. Parkinsonism Relat Disord 2002; 9(1):61.
92. Sampaio C, FERREIRA JJ, Costa J. Evidence-based medicine (EBM) applied to
Parkinson's disease treatment. Parkinsonism Relat Disord 2002; 9(1):7.
93. Tsuboi FERREIRA JJ, Uitti RJ, Delisle MB, FERREIRA JJ, Brefel-Courbon C,
Rascol O,Ghetti B, Murrell JR, Hutton M, Baker M, Wszolek ZK. Clinical features and
disease haplotypes of individuals with the N279K tau gene mutation: a comparison
of the pallidopontonigral degeneration kindred and a French family.Arch Neurol
2002;59(6):943-50.
94. FERREIRA JJ, Galitzky M, Thalamas C, Tiberge M, Montastruc JL, Sampaio C,
Rascol O. Effect of ropinirole on sleep onset: a randomized, placebo-controlled
study in healthy volunteers. Neurology 2002; 58(3):460-2.
95. Costa J, Rosa MM, FERREIRA JJ, Sampaio C, Vaz Carneiro A. Os efeitos cardíacos
da intoxicação aguda por antidepressivos tricíclicos: revisão sistemática da
literatura. Parte IV Rev Port Cardiol 2001; 20(10): 1021-1030.
96. Costa J, Rosa MM, FERREIRA JJ, Sampaio C, Vaz Carneiro A. Os efeitos cardíacos
da intoxicação aguda por antidepressivos tricíclicos: revisão sistemática da
literatura. Parte III Rev Port Cardiol 2001; 20(9): 901-909.
97. Costa J, de Oliveira EI, Rosa MM, FERREIRA JJ, Sampaio C, Carneiro AV. Os
efeitos cardíacos da intoxicação aguda por antidepressivos tricíclicos: revisão
sistemática da literatura. Parte II Rev Port Cardiol 2001; 20(7-8):765-72.
98. Costa J, Rosa MM, FERREIRA JJ, Sampaio C, Vaz Carneiro A. Os efeitos cardíacos
da intoxicação aguda por antidepressivos tricíclicos: revisão sistemática da
literatura. Parte I Rev Port Cardiol 2001; 20(6):671-8.
99. Rascol O, FERREIRA JJ, Montastruc JL. Somnolence diurne anormale, “attaques
de sommeil” et médicaments antiparkinsoniens. Rev Neurol (Paris) 2001; 157
(10):1313-1323.
100.
Sampaio C, FERREIRA JJ, Pona N, Coelho M, Costa J. Botulinum toxin
type A in stroke induced spasticity: is it clinically usefull? Saudi Journal of Disability
and Rehabilitation, 7 (2): 79-164.
101.
Sampaio C, FERREIRA JJ, Costa J. Numbers needed for treatment and
their respective confidence intervals: useful tools to assess clinical significance and
uncertainty associated with medical interventions]. Rev Port Cardiol. 2000;
19(12):1303-8.
102.
Rascol O, FERREIRA JJ, Thalamas C, Galitzky M, Montastruc JL.
Dopamine agonists: their role in the management of Parkinson's Disease. Adv
Neurol 2001; 86:301-9.
103.
FERREIRA JJ, Thalamas C, Montastruc JL, Castro-Caldas A, Rascol O.
Levodopa monotherapy can induce "sleep attacks" in Parkinson's Disease patients.
J Neurol 2001; 248(5):426-7.
104.
Montastruc JL, Brefel-Courbon C, Senard JM, Bagheri FERREIRA JJ,
FERREIRA JJ, Rascol O, Lapeyre-Mestre M. Sleep attacks and antiparkinsonian
drugs: a pilot prospective pharmacoepidemiologic study. Clin Neuropharmacol
2001; 24(3):181-3.
105.
FERREIRA JJ, Rascol O. Drug related sleep disturbances and Parkinson's
Disease: effects of dopaminergic antiparkinsonian drugs on sleep and wakefulness.
European Journal of Neurology 7 (Suppl. 4), 26-35.
106.
The Epidemiologic Study of Dystonia in Europe (ESDE) Collaborative Group.
A prevalence study of primary dystonia in eight European countries. Journal of
Neurology 2000; 247:787-792.
107.
FERREIRA JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks in
Parkinson's disease. Lancet 2000; 356(9229):597.
108.
FERREIRA JJ, Rascol O. Prevention and therapeutic strategies for
levodopa-induced dyskinesias in Parkinson’s disease. Current Opinion in Neurology
2000; 13 (4): 431-436.
109.
FERREIRA JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks and
Parkinson's disease treatment. Lancet. 2000; 355(9212):1333-4.
110.
Martins IP, FERREIRA JJ, Borges L. Acquired procedural dyscalculia
associated to a left parietal lesion in a child. Child Neuropsychology 1999; 5
(4):265-73.
111.
The Epidemiologic Study of Dystonia in Europe (ESDE) Collaborative Group.
Sex-related influences on the frequency and age of onset of primary dystonia.
Neurology. 1999; 53(8):1871-3.
112.
FERREIRA JJ, Costa J, Nunes S, Macedo A, Sampaio C. Distonia muscular
com instalação imediata após traumatismo periférico: implicações fisiopatológicas e
terapêuticas. Revista do Interno 1999; 10:29-35.
113.
FERREIRA JJ, Sampaio C. Critical Assessment of Articles on Controlled
Clinical Trials: Results. Acta Médica Portuguesa 1998; 11:755-760.
114.
Sampaio C, FERREIRA JJ. Critical Assessment of Articles on Controlled
Clinical Trials: Planning. Acta Médica Portuguesa 1998; 11:749-754.
115.
Sampaio C, FERREIRA JJ. Cochrane Collaboration: What is it? What is it
for? How does it contribute to the practice of Evidence Based Medicine. Acta
Médica Portuguesa 1998; 11:739-744.
116.
Ferro JM, Pinto AN, Falcão I, Rodrigues G, FERREIRA JJ, Falcão F,
Azevedo E, Canhão P, Melo TP, Rosa MJ, Oliveira V, Salgado AV. The diagnosis of
stroke by the nonneurologist. A validation study. Stroke 1998; 29:1106-1109.
117.
Sampaio C, FERREIRA JJ, Simões F, Rosas MJ, Magalhães M, Correia AP,
Bastos-Lima A, Martins R, Castro-Caldas A. DYSBOT: a single-blind, randomized
parallel study to determine whether any differences can be detected in the efficacy
and tolerability of two formulations of botulinum toxin type A - Dysport and Botox assuming a ratio of 4:1. Movement Disorders 1997; 12, 6: 1013-1018.
118.
Sampaio C, FERREIRA JJ, Pinto AN, Crespo M, Ferro JM, Castro-Caldas A.
Botulinum toxin type A for the treatment of arm and hand spasticity in stroke
patients. Clinical Rehabilitation 1997; 11:3-7.
119.
Quaresma J, Valadas E, FERREIRA JJ. Neurosyphilis and AIDS. Acta
Médica Portuguesa 1995; 5: 313-317.
120.
Martins R, Simões F, Garrett et al (Grupo de Estudo PARJUPAR). Selegilina
e/ou bromocriptina nos estadios iniciais da Doença de Parkinson (Estudo Parjupar):
justificação, metodologia e resultados da 1ª análise interina. Revista Portuguesa de
Neurologia 1993; 2, 4:199-204.
121.
Sampaio C, Castro-Caldas A, Pinto L, Apolinário P, Rosa MM, FERREIRA
JJ. Tratamento das distonias focais e hemiespasmo facial com toxina botulínica
tipo A. Revista Portuguesa de Neurologia 1992; 1, 4:55-61.